ESR1 and breast carcinoma: Given the short-lived duration of GIV in recipient breast cancer cells after separation from MSCs we observed in our studies (Figure 6E), ER+ breast cancer cells upon landing in the bone marrow may then need to re-establish contacts with MSCs in bone marrow to maintain expression of GIV.